Physician profile
Richard E Tepper
NPI 1588639165
$1,331.61
in general payments reported to CMS, 2019-2025
14 companies · $80.25 in 2025
The $80.25 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $279 · 2021: $113 · 2022: $169 · 2023: $183 · 2024: $105 · 2025: $80.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $348 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $348.06 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $287.33 | 2019-2024 | Arikayce |
| Janssen Biotech, INC. | $239.16 | 2020-2023 | Prezcobix |
| Gilead Sciences, INC. | $179.70 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $167.05 | 2019-2025 | Zerbaxa, Delstrigo, Pifeltro |
| Paratek Pharmaceuticals, INC. | $96.07 | 2019-2024 | Nuzyra |
| Abbvie INC. | $84.93 | 2019-2023 | Dalvance, Mavyret |
| Viiv Healthcare Company | $68.49 | 2019-2022 | |
| Vyera Pharmaceuticals, LLC | $41.40 | 2019-2022 | |
| Astellas Pharma US INC | $39.58 | 2019-2021 | |
| Allergan, INC. | $34.83 | 2020 | |
| Napo Pharmaceuticals INC | $31.79 | 2019-2021 | |
| Melinta Therapeutics, LLC | $24.12 | 2019 | |
| La Jolla Pharmaceutical Company | $21.63 | 2025 | Zevtera |
| Cumberland Pharmaceuticals, INC. | $15.53 | 2025 | Vibativ |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Tepper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.